The extreme potency of the plant toxin, ricin, is due to its enzymatic subunit, RTA, which 26 inactivates mammalian ribosomes with near perfect efficiency. Here we characterized, at the 27 functional and structural levels, seven alpaca single-domain antibodies (VHHs) previously 28 reported to recognize epitopes in proximity to RTA's active site. Three of the VHHs, V2A11, 29 V8E6 and V2G10, were potent inhibitors of RTA in vitro and protected Vero cells from ricin 30 when expressed as intracellular antibodies ("intrabodies"). Crystal structure analysis revealed 31 that the complementarity-determining region 3 (CDR3) elements of V2A11 and V8E6 penetrate 32 RTA's active site and interact with key catalytic residues. V2G10, in contrast, sits atop the 33 enzymatic pocket and occludes substrate accessibility. The other four VHHs also 34 penetrated/occluded RTA's active site, but lacked sufficient binding affinities to outcompete 35 RTA-ribosome interactions. Intracellular delivery of high-affinity, single-domain antibodies may 36 offer a new avenue in the development of countermeasures against ricin toxin. 37 38 3 39 65 Glu177 stabilizes the actual cleavage of the N-glycosidic bond. The role of Trp211 in catalysis 66 remains unknown. These catalytic residues, as well as the chemistry of the SRL depurination 67 reaction is conserved among other members of the ribosome-inactivating protein (RIP) 68 superfamily of toxins, including Shiga toxins 1 (Stx1) and 2 (Stx2) from foodborne Escherichia 69 coli (9). 70 With the capacity to inactivate >1500 ribosomes per minute (10), RTA's active site is an 71 obvious target to consider when designing therapeutics to arrest the effects of ricin toxin 72 exposure. In fact, early efforts successfully identified substrate analogues (e.g., pteroic acid, 73 131 performed Spearman correlation analysis to examine the relationship between in vitro RTA 132 inhibition and VHH binding affinity at both high and low antibody:RTA molar ratios (Figure 133 1E,F). There was indeed a correlation between RTA inhibitory activity and VHH dissociation 134 constants (KD), although a stronger relationship with RTA inhibitory activity and dissociation 135 rates (Koff). These results indicate that the stability of the antibody-antigen complex is critical for 136 potent inhibition of ricin in cell based killing assays and RTA in in vitro assays. 137 138
Introduction
Ricin is an extremely potent biological toxin derived from the castor bean (Ricinus 41 communis). It has a long history in the development of immunotoxins aimed at combating B cell 42 lymphomas and other cancers (1). Yet, ricin is equally renowned as a biothreat agent, especially 43 if dispersed by aerosol (2). Ricin's galactose/N-acetylgalactosamine-binding lectin subunit, RTB, 44 mediates toxin endocytosis and retrograde transport to the endoplasmic reticulum (ER) of 45 mammalian cells. In the ER lumen, ricin's enzymatic subunit, RTA, is liberated from RTB and 46 retro-translocated into the cytoplasm where it inactivates ribosomes with remarkable efficiency 47 (3, 4) . Activation of the ribotoxic stress response (RSR) and multiple stress-activated protein 48 kinase (SAPK) pathways ensue, resulting in the triggering of programed cell death pathways. In 49 the context of the lung, ricin triggers acute lung injury characterized by a massive inflammatory 50 response driven by IL-1, IL-6 and members of the tumor necrosis factor-a (TNF-a) superfamily, 51 triggering destruction of the lung epithelium, vascular leak, and edema (5). 52 The catalytic mechanism by which RTA disables mammalian ribosomes was elucidated three 53 decades ago when the X-ray crystal structure of ricin and its enzymatic activities were resolved 54 more or less simultaneously (6, 7) . Endo and colleagues demonstrated that RTA is an RNA N-55 glycosidase (EC 3.2.2.22 ) that depurinates a single adenosine residue within the sarcin-ricin loop 56 (SRL) of the 28S rRNA, an activity measurable in in vitro translation assays (6) . The SRL, one 57 of the longest conserved stretches of rRNA sequence, makes direct interactions with the GTP-58 binding domains of elongation factors like EF-Tu and is therefore indispensable for peptide 59 elongation. The depurination reaction is confined to RTA's active site, a large solvent-exposed 60 cleft on one face of the molecule that accommodates the protruding adenine (A) within the 61 conserved GAGA motif of the mammalian SRL. The five critical residues associated with RTA's 62 enzymatic activity have been defined by site-directed mutagenesis and include Tyr80, Tyr123, 63 Glu177, Arg180, and Trp211 (8). Tyr80 and Tyr123 serve to stabilize the adenine base substrate 64 via a π-stacking network. Arg180 is involved in protonation of the adenine leaving group while 4 guanine-like compounds) with modest RTA inhibitory activity in vitro (9), while other groups 74 identified molecules capable of trapping RTA's active site in a closed conformation (11) . 75 However, issues related to solubility, limited potency and/or biodistribution have severely 76 curtailed the use of those small molecule inhibitors in cell-based assays and animal models of 77 ricin intoxication (12). High-throughput, cell-based screens run in parallel as a complementary 78 means of identifying novel ricin inhibitors yielded compounds that targeted host proteins 79 associated with toxin trafficking and SAPK pathways, but not ricin itself (13, 14) . 80 In the past decade, camelid-derived, single-domain antibodies, commonly referred to as 81 VHHs or nanobodies, have received enormous attention for their potential as therapeutics against 82 emerging infectious disease and biothreat agents, including botulinum neurotoxin (BoNT), 83 anthrax toxin, and Shiga toxin (15) (16) (17) (18) . VHHs are small (13-16 kDa) immunoglobulin elements 84 amenable to expression in E. coli and surface display on bacteriophage M13. VHHs are also 85 highly soluble and thermostable. Of particular relevance to RTA is the reported propensity of 86 VHHs to target active site clefts and enzymatic pockets, as shown for lysozyme, a-amylase and 87 others (19, 20) . We recently described a collection of 21 VHHs that bind in immediate proximity 88 to or overlapping with RTA's active site, as demonstrated by epitope mapping studies using 89 hydrogen deuterium exchange (HDX) (21, 22) . In this report we have characterized seven of 90 those VHHs and demonstrate that three are potent inhibitors of RTA's enzymatic activity in in 91 vitro assay and when expressed as intracellular antibodies ("intrabodies") within the cytoplasm 92 of target cells. We then solved X-ray crystal structures of each of the VHHs in complex with 93 RTA, which revealed direct interactions with the catalytic residues associated with depurination 94 of the SRL.
96

Results
97
Identification of VHHs with potent RTA inhibitory activity. 98 We recently identified, through a strategic series of masking and targeted elutions, a collection of 99 21 VHHs that recognized spatially-distinct epitopes along the rim of RTA's active site (Figure 100 S1) (21, 22) . A total of seven were chosen for further examination, ultimately because we were 101 able to successfully solve the crystal structure of each in complex with RTA (Table 1; Figure 102 S1). Two of the VHHs, V2A11 and V6H8, derive from different alpaca libraries but share high 103 degree of CDR3 primary amino acid sequence identity (69%), possibly indicative of a similar 104 mode of interaction with RTA ( Figure S1 ). Three other VHHs, V8E6, V6A7 and V6A6, 105 constitute a clonal family, as evidenced by >80% identity in CDR3 (Figure S1 ). In addition, 106 V6D4 was one of only two VHHs among the nearly two dozen previously characterized active 107 5 site-targeting VHHs with detectable toxin-neutralizing activity in a Vero cell assay (Figure S1 ). 108 The binding affinities of the seven VHHs for RTA were determined by surface plasmon 109 resonance (SPR) and ranged from 0.3 nM to ~11 nM (Table 1: Figure S2 ). 110 The effect of the seven VHHs on RTA's capacity to inactivate ribosomes was evaluated in 111 a cell-free, luciferase-based in vitro translation (IVT) assay, as described in detail in the 112 Materials and Methods. RTA (EC90; 0.75 nM) was mixed with VHHs across a dose range and 113 then added to the IVT cocktail. Luciferase production at 90 min served as the proxy for protein 114 synthesis and ribosome activity. Three VHHs (V2A11, V8E6 and V2G10) had high RTA 115 inhibitory activity (>70%), one (V6A7) had intermediate activity (30-70%), and the remaining 116 three VHHs (V6A6, V6H8 and V6D4) had low or undetectable inhibitory activity (Figure 1A) . 117 The ability of the seven VHHs to neutralize RTA was dose-dependent ( Figure 1B) and correlated 118 directly with binding affinity (KD; Tables 1, S1). The relationship between binding affinity and 119 RTA inhibition is exemplified by the three clonally related VHHs, V8E6, V6A7 and V6A6, 120 whose RTA neutralizing activities (high, medium and low, respectively) tracked inversely with 121 their dissociation constants (0.42 nM, 4.2 nM and 10.9 nM, respectively; Table 1 ). 122 To confirm that the VHHs actually interfere with RTA's RNA N-glycosidase activity, we 123 tested the antibodies in an rRNA depurination reaction with yeast ribosomes as substrate (23). 124 Overall, the trends were nearly identical to what was observed in the IVT assay: V2A11, V8E6 125 and V2G10 were potent inhibitors of RTA's depurination activity, while V6H8, V6A6 and 126 V6D4 were weak inhibitors (Figure 1 C, D) . V6A7 and V6H8 inhibited RTA in the depurination 127 assay more effectively than in the IVT assay, possibly reflecting slight differences in the 128 sensitivity and/or stringency of the assays. 129 In previous studies we and others have reported a relationship between antibody binding 130 affinity and toxin-neutralizing activity, at least in cell-based assays (22) . Therefore, we 6 RTA-specific VHH expressed as intrabodies render Vero cells resistant to ricin toxin. With 139 the exception of V6D4, the VHHs described above do not to have toxin-neutralizing activity in a 140 cell-based cytotoxicity assay ( Figure S1 ) (21, 22) . Nonetheless, we hypothesized that the VHHs, 141 by virtue of the fact that they are postulated to bind epitopes in immediate proximity of RTA's 142 active site, could protect Vero cells from the effects of ricin if they were successfully expressed 143 in the cell cytoplasm as intracellular antibodies or "intrabodies." Intrabodies, which refers to the 144 cytosolic or organelle-specific expression of antibody variable regions in the form of single chain 145 Fv (scFv) or VHHs, have been exploited as tools to knock-down intrinsic cytosolic targets like 146 the EGF receptor, as well as extrinsic cytosolic targets like viral antigens and even botulinum 147 neurotoxin (BoNT) (17, 24) . Theoretically, RTA is an ideal intrabody target, since it is exposed 148 to the cytosolic environment immediately following retro-translocation across the ER membrane. 149 To test this hypothesis, we constructed pCDNA3.1-based mammalian expression vectors with an escalating scale of ricin toxin and a shift in EC50 values relative to mock-transfected cells 169 was interpreted as being the result of intracellular VHH activity. 170 We found that Vero cells transfected with VHHs V2A11, V8E6, or V2G10 were 171 significantly more resistant to ricin, as compared to mock transfected cells. For example, cells 172 transfected with V2A11 or V2G10 resulted in ~20-fold increase in EC50 values, while 173 transfection with V8E6 resulted in ~6-fold change (Figure 2B-I) . These three VHHs (V2A11, 174 V8E6, or V2G10) were also the most effective at neutralizing RTA in vitro, as shown in Figure   175 1. Transfection with V6A7 rendered the Vero cells resistant to low dose (but not high dose) ricin 176 challenge, whereas the three VHHs with the lowest binding affinities for RTA, namely V6H8, 177 V6A6, and V6D4, afforded no benefit. These results represent the first demonstration of 178 intrabody-mediated targeting of RTA and highlight the potential application of VHH-based 179 therapies in combatting other structurally conserved RIPs like Shiga toxins 1 and 2, whose active 180 sites are structurally conserved with RTA (25). The V6H8-RTA interaction is similar. It results in a total bsa of 2080 Å 2 and has an Sc score 219 of 0.684 ( Table 1) . The antibody-toxin interaction is also dominated by a CDR3 that penetrates Occupancy of RTA's Active Site by V8E6, V6A7 and V6A6 (Mode 1B) 251 Within Mode 1B, there were notable parallels in how V8E6, V6A7 and V6A6 engaged RTA, 252 which was not surprising considering the three VHHs share 85 to 91% amino acid sequence 253 identity ( Figure S1 ). V8E6 had the strongest binding affinity (KD = 0.42 nM) for RTA and was 254 the most effective at inhibiting RTA in vitro and when expressed as an intrabody (Table 1; 255 Figure 2 ). The co-crystal structure revealed that V8E6 buried 2367 Å 2 of solvent exposed 256 surface and had the highest shape complementarity in this subgroup with a score of 0.701, 257 accounting for its high binding affinity and potent RTA inhibitory activity (Figure 3C) Tyr104 obstructs RTA's Tyr123 (Figure 4C ). CDR1 and CDR2 contributions are also significant 262 with 8 H-bonds formed with RTA and a total of 972 Å 2 of buried surface area. 263 The co-crystal structure of V6A7-RTA revealed a buried surface area of 2,416 Å 2 (Table   264 1; Figure 3D ) CDR3 forms 10 hydrogen bonds with RTA and accounts for more than half the 265 total buried surface area (1325 Å 2 ). V6A7's CDR3 also occludes key RTA active site residues: 266 Tyr103 obstructs RTA Tyr80, while Tyr105 comes within 3.8 Å of RTA's Tyr123 (Figure 4D) . 267 As noted in Table 1 , V6A7 has a slightly lower shape complementarity with RTA (0.672), as 268 compared to V8E6 (0.701), likely contributing to their different binding affinities (4.2 vs. 0.42 269 269 nM). 270 Finally, V6A6 buried the largest amount of solvent exposed surface with RTA (bsa = 2,519 271 Å 2 ), but had the lowest shape complementarity (Sc = 0.657) and the lowest overall binding 272 affinity (10.9 nM) ( (Figure 4E) . Therefore, binding affinity, rather than epitope specificity, 277 accounts for the failure of V6A6 to inhibit RTA activity in vitro and intracellularly as an Ironically, the CDR3 elements also account for the relatively large RMSD (1.4 to 2.0 Å) 290 between Modes 1A and 1B, compared to the RMSD (0.5 to 0.9 Å) within the individual Modes. 291 Specifically, the difference in CDR3 configurations between VHHs in Mode 1A and Mode 1B is 292 11 determined in large part by the residue located at position 100 (101 in V6A7). In Mode 1A that 293 residue is a Trp, while in Mode 1B that residue is a Gly (Figure S1) . A Gly at position 100 is 294 consequential because it permits bulky residues to be positioned at residue 104 or 105 (e.g., Tyr-295 105 in V6A7; Tyr-104 in V8E6/V6A6), in addition to influencing the spatial location of abutting 296 residues (Thr-102, 297 Ser-101, His-102, and Tyr-103 in V8E6), relative to the corresponding residues in CDR3 of 298 V2A11 and V6H8 (Figure S8B) . The CDR3 configurations of Modes 1A and 1B VHHs are also 299 influenced by CDR1 in that in Mode 1A, residue 32 is a Tyr (V2A11) or a His (V6H8), which 300 would sterically clash with a bulky residue located in CDR3 at position 104 or 105 ( Figure S5 ). 301 Altogether, local structural differences in CDR3 configurations result in appreciably different 302 interactions with RTA between VHHs in Modes 1A and 1B. 303 The CDR1 and CDR2 elements also contributed to the interface with RTA, but strictly (Table 1) .
315
Interactions of V2G10 and V6D4 with RTA's active site. 316 We next analyzed the co-crystal structures of the remaining two complexes, V2G10-RTA and 317 V6D4-RTA. V2G10, a potent inhibitor of RTA, and V6D4, a weak inhibitor of RTA, each 318 formed a cap over RTA's active site (Figure 3F-G) . Compared to the five VHHs in Mode 1, 319 V2G10 and V6D4 are rotated counterclockwise by ~99° and ~165°, respectively, around RTA's 320 active site ( Figure S8 ). In addition, their CDR3 elements are tethered to the surface of the VHH 321 molecule, physically restricting their ability to project into the active site cleft. In V2G10, 322 tethering is the result of hydrophobic interactions between CDR3 residues Ala-118 and Tyr-124 323 12 and framework region (FR) residues Phe-44 and Phe-55, as well as a salt bridge between CDR3 324 Arg-119 and FR residue Asp-71. In the case of V6D4, the CDR3 element is restrained by a 325 disulfide bond between CDR2 Cys50 and CDR3 Cys105 ( Figure S8) . 326 Overall, the V2G10-RTA interaction buried 1,965 Å 2 with an Sc score of 0.665 (Table   327 1). V2G10's CDR1 and CDR2 elements established 3 hydrogen bonds with RTA and bury a total 328 of 892 Å 2 of surface area. CDR1 makes contacts with RTA α-helix C, helix 310 b, and β-strands i 329 and j, while CDR2 interacts primarily with α-helix G and β-strands i and j. CDR3 contacts 330 RTA's α-helices B, C, and G, helix 310 b, β-strand i, and the g-B loop, buries 1194 Å 2 of solvent 331 exposed surface area, and forms a total of 7 hydrogen bonds with RTA. The CDR3 comes within 332 12 Å 2 of the catalytic residue, Tyr-80 (Figure 5A) . 333 The V6D4-RTA interaction generated six hydrogen bonds and buried 1,746 Å 2 of surface 334 area with an overall Sc of 0.689 ( Table 1) . V6D4's CDR1 and CDR2 made minimal contact with 335 RTA, burying 12 Å 2 and no hydrogen bonds. In contrast, CDR3 buried 1,125 Å 2 and formed 6 336 hydrogen bonds. CDR3 interacted with RTA α-helices B, C, and G as well as loops c-d and e-f. 337 In an interesting twist, the presence of a proline residue (Pro-106) in the proximal region of 338 CDR3 creates a partially unrestricted bend within the VHH main chain that positions Arg108 and 339 Pro109 within ~3.5 Å of Tyr80 (Figure 5B) . 340 The crystal structure of V6D4-RTA revealed that V6D4 FR residues (Tyr-45, Gly-46, Figure S9) . Although V6D4 is a weak inhibitor of RTA in vitro, it was 344 the only VHH among the seven that had demonstrable toxin-neutralizing activity in a cell-based 345 assay (Figure S1) , which we speculate may be due to contact with RTA's a-helix B, a known 346 neutralizing hotspot. In this regard, it is interesting to point out that previous epitope mapping 347 studies by HX-MS did not differentiate V2G10 from the Mode 1 family of VHHs, but did 348 successfully classify V6D4 as being unique, largely because of its interaction with a-helix B 349 (21). away from the antibody surface in an "extended" conformation, while V2G10 is representative 357 of VHHs in which the CDR3 is "pinned" to the surface of the antibody (Table S3 ). While our 358 sample size remains small (seven deposited to PDB, plus six pending for "extended"; 11 359 deposited to PDB, plus 10 pending for "pinned"), the overall alignment is remarkable (Table S3 ; and incompatible with cell and animal models of ricin toxicity (12, 29) . In an effort to 380 circumvent the issue of solubility, high-throughput, cell-based screens were performed with 381 commercially available small molecule libraries. While compounds were identified that were 382 capable of protecting cells from ricin-induced killing, the molecules invariably targeted host cell 383 processes, rather than the toxin itself (13, 14, 30) . 384 
14
It is therefore highly significant that we have discovered three VHHs with potent RTA 385 inhibitory activity: V2A11, V8E6 and V2G10. Two of the three antibodies, V2A11 and V8E6, 386 representing binding Modes 1A and 1B, respectively, physically occupy RTA's active site by 387 virtue of their CDR3 elements, as revealed by the X-ray crystal structure of the VHH-RTA 388 complex. In this respect, V2A11 and V8E6 are textbook examples of the propensity of VHHs to 389 target concave epitopes such as the enzymatic pockets of hen egg white lysozyme and a-amylase 390 (19, 20, (31) (32) (33) , the CD4-binding pocket of HIV-1 gp120 (34), and the receptor-binding pocket 391 of poliovirus (35). The proclivity of camelid heavy chain-only antibodies for enzymatic clefts 392 has been attributed to their "prolate" shape and rigidification of CDR3 through FR interactions, 393 as well as non-canonical disulfide bonds that alleviate the entropic penalty that would normally 394 be associated with extended CDR3 elements (15, 33) . The interactions of VHHs with active site 395 pockets can be so exquisite that they compete with small molecule substrate analogs and mimic 396 native substrates at the atomic level (19, 20, 36) . 397 Indeed, we found that VHHs in Mode 1A and 1B had CDR3 residues that directly interacted 398 with RTA's catalytic residues Tyr80 and Tyr123, steering Tyr80 into a configuration that would 399 effectively perturb the π-stacking network required for depurination of SRL (Figure S6) . Mode 1 400 VHH CDR3 elements further perturbed RTA's RNA N-glycosidase machinery by forming H-401 bonds with Arg180, effectively pulling this residue away from the target N-3 atom within the 402 adenine ring. By way of comparison, when RTA is bound to a substrate analog, AMP, Arg-180 403 is 3Å from the N-3 atom (PDB: 3HIO), whereas Arg-180 is 3.9 Å away from the N-3 atom when 404 RTA is bound to V2A11 (Figure S6) . The greater distance between Arg-180 and substrate when 405 RTA is bound to Mode 1 VHHs would compromise proton transfer to the N-3 atom within the 406 adenine ring, effectively impeding hydrolysis of the N-9 to C-1' bond within the adenosine 407 residue within the SRL substrate (27). 408 The other three VHHs within Mode 1, V6H8, V6A7 and V6A6, engaged with RTA active site 409 residues in an identical fashion as V2A11 (in the case of V6H8) and V8E6 (in the case of V6A7 410 and V6A6), but were ineffective as RTA inhibitors. The primary difference between the potent 411 and impotent antibodies is binding kinetics: V2A11 and V8E6 have equilibrium dissociation 412 constants (KD) of <1 nM and off-rates of <6 x 10 -4 (1/s), whereas V6H8, V6A7 and V6A6 have 413 KD values of 4-10 nM and off-rates ranging from 4-20 x 10 -3 (1/s). These results reveal a 414 15 minimum binding/dissociation threshold necessary to effectively neutralize RTA, a topic that 415 will be discussed further below. 416 The third potent inhibitor of ricin, namely V2G10, sits atop and caps (rather than penetrates) 417 RTA's active site. This alternative mode of attack (vis a vis V2A11 and V8E6) is due to 418 V2G10's CDR3 element being tethered to the surface of the antibody and, therefore, restricted 419 from projecting away from the core immunoglobulin fold and interacting with concave epitopes 420 (33). We speculate that the pinned back CDR3 configuration is predetermined by the IGHV3-3 421 VH gene usage and represents one of at least two alpaca VHH archetypes. Despite these different 422 binding modalities, V2G10's KD (0.28 nM) and off-rate (6.2 x 10 -4 1/s) were identical to those of 423 V2A11 and V8E6 and therefore over the minimum threshold required to inhibit RTA activity. Table S1 . Molecular graphics were prepared using PyMOL(Schrodinger) (DeLano 518 Scientific LLC, Palo Alto, CA). 519 520 Accession Numbers. The structures generated in this study were deposited in the Protein Data 521 Bank (PDB; http://www.rcsb.org/pdb/). The accession numbers are presented in Table 1 and   522   Table S1 . penicillin/streptomycin at 37°C (5% CO2). Cells were transfected in 6-well (ELISAs) or 96-well 538 plates (cytotoxicity assays) as recommended for Lipofectamine™ 3000 transfection protocol 539 (Life Technologies, Carlsbad, CA). For ELISAs, cells were washed 48 h post-transfection twice 540 in ice-cold PBS. RIPA Lysis Buffer (50 mM Tris-HCl pH7.5, 150 mM NaCl, 1% NP-40, 0.1% 541 SDS, and 1% Na-deoxycholate; 150 μL) was added and cells were incubated for 5 minutes on ice 542 with occasional gentle rocking to ensure well coverage. Cells were transferred to chilled 2 mL 543 screw cap tubes with 1 mm glass beads by scraping and pipetting followed by homogenization at 544 5 m/s for 5 s. Cell lysates were replaced on ice for 30 min with one more homogenization step, 545 followed by centrifugation at 15,700 x g for 10 min at 4°C. 546 For cytotoxicity assays, cells were transfected for 24 h before ricin treatment. Medium 547 was aspirated from cells, replaced with 100 μL ricin toxin serially diluted in DMEM, and 548 incubated at 37°C for 2 h. Ricin was then aspirated from cells and replaced with 100 μL 549 DMEM. Cells were incubated for 48 h at 37°C. Viability was determined using Cell Titer-Glo® 550 (Promega) and a Spectramax L Microplate Reader (Molecular Devices) and measured as a 551 percentage of live control cells (transfected, but not treated with ricin). 552 553 ELISAs. To detect intrabody levels, 96-well ELISA plates (Immulon™ 4HBX; ThermoFisher) 554 were coated overnight at with 1 μg/mL SyH7 (anti-RTA mAb) (50) or 4 μg/mL asialofetuin 555 (ASF; Sigma-Aldrich) in PBS. Plates were washed and blocked for 2 h at room temperature. 556 Following block, ricin or RTA (1 μg/mL in PBS) was applied to ELISA plates for 1 h. 557 Transfected cell lysate was added in triplicate and serially diluted across plate for 1 h. Plates 
